Remove Aortic Remove Heart Disease Remove Tricuspid
article thumbnail

Smidt Heart Institute Physicians Advance Transcatheter Tricuspid Valve Replacement

DAIC

Physicians in the Smidt Heart Institute at Cedars-Sinai have pioneered using a catheter-based approach to treat patients with tricuspid valve disease. The first 100 minimally invasive tricuspid procedures were done as part of the TRISCEND II clinical trial. Image by Getty. Image by Getty. Eduardo Marbán, MD, PhD.

Tricuspid 105
article thumbnail

Abbott Announces FDA Approval of First-of-its-kind Device to Repair Leaky Tricuspid Heart Valve, TriClip

DAIC

Food and Drug Administration (FDA) approval of its TriClip, a first-of-its-kind device to repair leaky tricuspid heart valve, for which more than 1.6 are affected by tricuspid regurgitation, 1 which can severely impact quality of life. Abbott has announced U.S million people in the U.S. are estimated to be affected. and Lynn C.

Tricuspid 105
article thumbnail

Tricuspid regurgitation: Frequency, clinical presentation, management and outcome among patients with severe left?sided valvular heart disease in Europe. Insights from the ESC?EORP Valvular Heart Disease II survey

European Journal of Heart Failure

Tricuspid regurgitation (TR): frequency, clinical presentation, management and outcome among patients with severe left-sided valvular heart disease in Europe. ESC-EORP, European Society of Cardiology-EURObservational Research Programme; TV, tricuspid valve.

article thumbnail

The Society of Thoracic Surgeons Launches New Valve Surgery Risk Calculators

DAIC

Tricuspid Valve Repair Existing literature on national surgical outcomes of isolated tricuspid valve repair or replacement is based on data from over a decade ago and may not reflect current practice results. Analysis of 13,587 patients undergoing isolated tricuspid valve surgery from 2017 to 2023 revealed a 5.5%

TAVR 111
article thumbnail

Edwards Lifesciences to Sell Critical Care to BD

DAIC

The sale enhances Edwards’ balance sheet flexibility for disciplined investments in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heart failure.

article thumbnail

Coronary microvascular dysfunction in patients undergoing transcatheter aortic valve implantation

Heart BMJ

Objectives This study aimed to evaluate the prognostic value of coronary microvascular dysfunction (CMD) at long term after transcatheter aortic valve implantation (TAVI) and to explore its relationship with extravalvular cardiac damage (EVCD). CMD was defined as IMR angio ≥30 units.

article thumbnail

Society of Cardiovascular Computed Tomography Annual Scientific Meeting SCCT24 Preview

DAIC

Attendees can join with their peers and participate in sessions on structural heart disease, congenital heart disease, guidelines and trials, AI/Machine learning, technical aspects of cardiac CT, coronary artery disease, vascular heart disease, debates and games and early career topics.